---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-072746"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:17:08.811812+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma receives Nasdaq non-compliance notice for MVLS below $35M

## Summary
- Received Nasdaq notice on Aug 1, 2025 for failing to maintain minimum MVLS of $35M for 30 consecutive business days.
- Non-compliance period identified as June 13, 2025 to July 31, 2025.
- Company has 180 days, until Jan 28, 2026, to regain compliance with MVLS of $35M+ for 10 consecutive business days.
- Also noted non-compliance with alternative listing rules 5550(b)(1) and 5550(b)(3).
- No immediate effect on listing; Company will monitor and consider options but cannot assure regaining compliance.

## SEC filing metadata
- accession: 0001213900-25-072746
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390025072746/0001213900-25-072746-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390025072746/ea0252082-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-072746
- JSON: https://secwatch.observer/filing/0001213900-25-072746.json
- Plain text: https://secwatch.observer/filing/0001213900-25-072746.txt

## Key facts
- Listing & Compliance Notices
  Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2), 5810(c)(3)(C)
  source text: August 1, 2025, Estrella Immunopharma, Inc. (the “ Company ”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires listed securities to maintain a minimum Market Value of Listed Securities (“ MVLS ”) of $35,000,000. The Company has not met this requirement for the 30 consecutive business days preceding the date of the notice. The notice indicated the period of non-compliance was from June 13, 2025, to July 31, 2025. The notice also not
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000121390025072746/0001213900-25-072746-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.